YB1-CD47

N/A

Report date: 2023/10/25 11:48:14

Base Information

Drug NameYB1-CD47
Drug Alias NameYB1-CD47
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Cluster of differentiation 47Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesThe University Of Hong Kong
China Registration ClassN/A

Develop Information

Active CompaniesHknd YB1 Pharmaceutical Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A